ASND vs PFE
ASND: Ascendis Pharma is a biopharma company leveraging its proprietary TransCon technology platform to develop best-in-class therapies for endocrine rare diseases and large-market conditions. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | ASND | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $238.90 | $29.85 | |
| Market cap as of 2026-07-29 (share count; price 2026-10-21) | n/a | $170.1B | |
| P/E as of 2026-10-21 | n/a | 39.28 | |
| Net margin FY2025, SEC XBRL | n/a | +12.4% | |
| ROE FY2025, SEC XBRL | n/a | +9.0% | |
| ROA FY2025, SEC XBRL | n/a | +3.7% | |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-28 | n/a | 0.74 | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | -1.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -14.8% | |
| Dividend yield as of 2026-09-02 | n/a | +6.2% | |
| Dividend streak (yrs) SEC XBRL | n/a | 11 | |
| Beta | 0.38 | 0.38 | |
| 1-year return as of 2026-10-21 close | +19.1% | +20.1% | PFE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.